Candidiasis

• EMA withdrawal · 2023-10-23
  EMA Application withdrawn: Vivjoa (oteseconazole) — Gedeon Richter Plc.

  The EMA has withdrawn the application for Vivjoa (oteseconazole) by Gedeon Richter Plc. for candidiasis.

• EMA withdrawal · 2021-08-20
  EMA Expired: Caspofungin Accord (caspofungin acetate) — Accord Healthcare S.L.U.

  EU assessment indicates Caspofungin Accord has expired status and is no longer active on the market.

• EMA withdrawal · 2009-08-04
  EMA Lapsed: Posaconazole SP (posaconazole) — Schering-Plough Europe

  EMA status shows Posaconazole SP has lapsed; therapeutic areas include candidiasis, mycoses, coccidioidomycosis, and aspergillosis.

• EMA withdrawal · 2007-03-21
  EMA Refused: Mycograb (recombinant human monoclonal antibody to hsp) — NeuTec Pharma plc

  EMA refused authorization for Mycograb, a recombinant human monoclonal antibody targeting hsp for candidiasis, by NeuTec Pharma plc.